Product logins

Find logins to all Clarivate products below.


Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout is a form of inflammatory arthritis caused by sustained hyperuricemia, or elevated serum uric acid (sUA) levels. This condition manifests through sudden and intense gout flares, causing significant discomfort. The therapeutic approach for acute flares differs from chronic gout management, and it is not the focus of this analysis. Chronic treatment aims to prevent recurrent gout attacks and limit joint damage by lowering sUA levels. Xanthine oxidase inhibitors (XOIs), especially the widely prescribed generic allopurinol, form the cornerstone of chronic gout treatment. For later lines of therapy, pegloticase (Krystexxa), a highly efficacious biological agent, is utilized. This report provides valuable insights into the use of these treatments in patients with newly diagnosed or recently treated chronic gout.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed chronic gout patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed chronic gout patients?
  • How has pegloticase been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of chronic gout patients receive drug therapy within 365 of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 of diagnosis?
  • What percentage of chronic gout patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…